Denmark
· Delayed Price · Currency is DKK ChemoMetec Statistics
Total Valuation
ChemoMetec has a market cap or net worth of DKK 7.32 billion. The enterprise value is 7.05 billion.
| Market Cap | 7.32B |
| Enterprise Value | 7.05B |
Important Dates
The last earnings date was Wednesday, February 4, 2026.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Oct 10, 2025 |
Share Statistics
ChemoMetec has 17.40 million shares outstanding. The number of shares has increased by 0.07% in one year.
| Current Share Class | 17.40M |
| Shares Outstanding | 17.40M |
| Shares Change (YoY) | +0.07% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 3.75% |
| Owned by Institutions (%) | 35.11% |
| Float | 16.75M |
Valuation Ratios
The trailing PE ratio is 41.34 and the forward PE ratio is 28.22. ChemoMetec's PEG ratio is 1.36.
| PE Ratio | 41.34 |
| Forward PE | 28.22 |
| PS Ratio | 14.84 |
| PB Ratio | 11.21 |
| P/TBV Ratio | 15.09 |
| P/FCF Ratio | 40.82 |
| P/OCF Ratio | 34.83 |
| PEG Ratio | 1.36 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.86, with an EV/FCF ratio of 39.32.
| EV / Earnings | 39.80 |
| EV / Sales | 14.29 |
| EV / EBITDA | 28.86 |
| EV / EBIT | 30.49 |
| EV / FCF | 39.32 |
Financial Position
The company has a current ratio of 3.93, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.93 |
| Quick Ratio | 3.02 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | 0.03 |
| Interest Coverage | 172.83 |
Financial Efficiency
Return on equity (ROE) is 28.31% and return on invested capital (ROIC) is 46.70%.
| Return on Equity (ROE) | 28.31% |
| Return on Assets (ROA) | 19.08% |
| Return on Invested Capital (ROIC) | 46.70% |
| Return on Capital Employed (ROCE) | 35.01% |
| Weighted Average Cost of Capital (WACC) | 11.69% |
| Revenue Per Employee | 2.87M |
| Profits Per Employee | 1.03M |
| Employee Count | 172 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 0.18 |
Taxes
In the past 12 months, ChemoMetec has paid 51.62 million in taxes.
| Income Tax | 51.62M |
| Effective Tax Rate | 22.58% |
Stock Price Statistics
The stock price has decreased by -29.64% in the last 52 weeks. The beta is 1.35, so ChemoMetec's price volatility has been higher than the market average.
| Beta (5Y) | 1.35 |
| 52-Week Price Change | -29.64% |
| 50-Day Moving Average | 578.41 |
| 200-Day Moving Average | 599.39 |
| Relative Strength Index (RSI) | 31.08 |
| Average Volume (20 Days) | 114,979 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ChemoMetec had revenue of DKK 493.12 million and earned 177.03 million in profits. Earnings per share was 10.17.
| Revenue | 493.12M |
| Gross Profit | 471.14M |
| Operating Income | 231.08M |
| Pretax Income | 228.65M |
| Net Income | 177.03M |
| EBITDA | 244.16M |
| EBIT | 231.08M |
| Earnings Per Share (EPS) | 10.17 |
Balance Sheet
The company has 274.66 million in cash and 5.21 million in debt, giving a net cash position of 269.45 million or 15.48 per share.
| Cash & Cash Equivalents | 274.66M |
| Total Debt | 5.21M |
| Net Cash | 269.45M |
| Net Cash Per Share | 15.48 |
| Equity (Book Value) | 652.59M |
| Book Value Per Share | 37.50 |
| Working Capital | 361.17M |
Cash Flow
In the last 12 months, operating cash flow was 210.08 million and capital expenditures -30.85 million, giving a free cash flow of 179.23 million.
| Operating Cash Flow | 210.08M |
| Capital Expenditures | -30.85M |
| Free Cash Flow | 179.23M |
| FCF Per Share | 10.30 |
Margins
Gross margin is 95.54%, with operating and profit margins of 46.86% and 35.90%.
| Gross Margin | 95.54% |
| Operating Margin | 46.86% |
| Pretax Margin | 46.37% |
| Profit Margin | 35.90% |
| EBITDA Margin | 49.51% |
| EBIT Margin | 46.86% |
| FCF Margin | 36.35% |
Dividends & Yields
This stock pays an annual dividend of 7.00, which amounts to a dividend yield of 1.67%.
| Dividend Per Share | 7.00 |
| Dividend Yield | 1.67% |
| Dividend Growth (YoY) | 75.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 68.81% |
| Buyback Yield | -0.07% |
| Shareholder Yield | 1.59% |
| Earnings Yield | 2.42% |
| FCF Yield | 2.45% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ChemoMetec has an Altman Z-Score of 49.32 and a Piotroski F-Score of 6.
| Altman Z-Score | 49.32 |
| Piotroski F-Score | 6 |